Fig. 1
From: Accumulation of copy number alterations and clinical progression across advanced prostate cancer
CN-300 cohort and association of the burden of copy number alteration with metastatic states. A Map demonstrating all UK STAMPEDE trial sites recruiting patients included in the CN-300 cohort. B Distribution of burden of copy number (CN) alteration (%) in tumour-enriched region of index core split by metastatic states (N=284; 16 metastatic patients with unknown designation for low versus high volume were excluded). C–E Alteration frequency (%) of patients with at least one segment of loss mapped to denoted cytobands in C M0N1 versus M0N0; D M1 low versus M0N1; E M1 high versus M1 low. F–H Alteration frequency (%) of patients with at least one segment of gain mapped to denoted cytobands in F M0N1 versus M0N0; G M1 low versus M0N1; and H M1 high versus M1 low